Navigation Links
EPA holds seminar on air pollution and cardiovascular disease
Date:5/20/2010

WASHINGTON The U.S. Environmental Protection Agency is sponsoring a seminar called "Breathe Cleaner, Live Longer: Understanding Air Pollution after 40 Years." The event is co-sponsored by the American Heart Association and the U.S. House of Representatives Committee on Science and Technology. World-renowned scientific experts will discuss the impacts of air pollution on life expectancy and cardiovascular disease, and how improvements in air quality have reduced illness.

The seminar is the first in a series that will be held throughout 2010 in Washington, D.C. as part of Air Science 40, a year-long celebration of how EPA's air research has made a difference in air pollution and its impacts on human health.

WHO: Kevin Teichman, Ph.D., deputy assistant administrator of EPA's Office of Research and Development
Rep. Bart Gordon, Chairman, Committee on Science and Technology, U.S. House of Representatives (invited)
Other EPA scientists
University scientists

WHAT: "Breathe Cleaner, Live Longer: Understanding Air Pollution after 40 Years"

WHEN: Friday, May 21, from 12:00 p.m. to 1:30 p.m.

WHERE: Rayburn House Office Building, Room 2325

To register for the seminar, contact Michelle Limes at the American Heart Association at 202-785-7949 or michelle.limes@heart.org.


'/>"/>

Contact: Dave Ryan
ryan.dave@epa.gov
202-564-7827
U.S. Environmental Protection Agency
Source:Eurekalert

Page: 1

Related biology news :

1. New ORNL carbon composite holds promise for bionics
2. Orange corn holds promise for reducing blindness, child death
3. New map of variation in maize genetics holds promise for developing new varieties
4. Energy experts helping Australian households reduce carbon emissions
5. Canadian research breakthrough holds promise for development of effective cancer therapies
6. Nanotechnology holds promise for STD drug delivery
7. New drug holds out promise of normal diet for sufferers of devastating PKU genetic disease
8. High blood sugars impact on immune system holds clues to improving islet cell transplants
9. Oral rinses used for tracking HPV-positive head and neck cancers holds promise for cancer screening
10. Research identifies type of vaccine that holds promise in protecting against TB
11. New synthetic form of protein holds promise to stop cancer spread
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... LONDON , June 2, 2016 ... has awarded the 44 million US Dollar project, ... Security Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... world leader in the production and implementation of Identity Management ... in January, however Decatur was selected ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, Biometrics & ... & Other Service  The latest report from ... of the global Border Security market . Visiongain ... billion in 2016. Now: In November 2015 ... and hardware technologies for advanced video surveillance. ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: